Photo taken from Vivek Subbiah/LinkedIn
Jan 19, 2024, 08:58
Vivek Subbiah: We need to break free from “me too” compounds
Vivek Subbiah shared on X/Twitter:
“Exciting times in the world of Anti-body drug conjugates – ADCs! Major companies racing to acquire ADCs, but it’s also time for innovation. We need to break free from “me too” compounds and explore the cutting-edge landscape of novel ADCs. Timely review out in Nature Reviews Clinical Oncology. Exploring the next generation of antibody–drug conjugates.”
View additional information.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.